|Bid||272.40 x 900|
|Ask||272.58 x 2900|
|Day's Range||271.72 - 275.32|
|52 Week Range||188.84 - 306.56|
|Beta (5Y Monthly)||0.95|
|PE Ratio (TTM)||39.63|
|Earnings Date||Jul 24, 2023 - Jul 28, 2023|
|Forward Dividend & Yield||3.00 (1.10%)|
|Ex-Dividend Date||Jun 29, 2023|
|1y Target Est||313.82|
Apple, Chevron, Accenture, Broadcom and Stryker are included in this Analyst Blog.
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Chevron Corporation (CVX) and Accenture plc (ACN).
Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on the stock.
LEESBURG, Va., May 24, 2023--Stryker launches Q Guidance System with Cranial Guidance Software, providing groundbreaking planning and guidance capabilities.
Because of their longevity, predictability, and stability, healthcare trends can persist for years. The companies covered today are fundamentally and technically robust stocks currently taking advantage of these trends.
HLN vs. SYK: Which Stock Is the Better Value Option?
Stryker (NYSE: SYK) and Medtronic (NYSE: MDT) are a pair of the biggest and most important medical-device and supply companies out there, but they're a bit different in the stability of the dividend income they offer to investors. Overall, Stryker's business is quite stable: It makes medical equipment, medical instruments, and surgical robotics for healthcare systems worldwide, and there isn't much in the way of rapidly shifting demand for its major segments. But it can reliably generate growth by investing in research and development (R&D) to make incremental improvements to its existing products, even if that growth is unlikely to be rapid due to the slow-growing nature of its markets. For example, developing more-advanced hip replacement products for use with its surgical robot system probably won't make investors rich overnight, but it'll keep the top and bottom lines expanding.
Kalamazoo, Michigan, May 10, 2023 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.75 per share payable July 31, 2023 to shareholders of record at the close of business on June 30, 2023, representing an increase of 7.9% versus the prior year and unchanged from the previous quarter. Stryker is one of the world’s leading medical technology companies and, together with its customers, is driven to make healthcare better. The company
Stryker, Boston Scientific, Zimmer Biomet and Insulet are part of the Zacks Industry Outlook article.
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. SYK, BSX, ZBH and PODD are well-poised to gain from the favorable factors.
Packing your portfolio with risky hyper-growth stocks might make you feel like a genius during a bull market, but when there's a downturn, your smile just might get turned upside down. As exciting as seeing rapidly rising share prices might be, your portfolio needs to be well-diversified, and that means you need a few companies that are stable in the face of turmoil, not to mention being capable of delivering some growth all the time. Thermo Fisher Scientific (NYSE: TMO) is a sturdy stock that's fit for holding for decades because it's one of the businesses that makes the entire biopharma sector run.
BAX vs. SYK: Which Stock Is the Better Value Option?
Stryker's (SYK) first-quarter earnings reflect strong performance across its segments. However, unfavorable currency movement hurts sales growth and rising costs affect margins.
Stryker (SYK) delivered earnings and revenue surprises of 7% and 4.91%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Medical technology company Stryker Corp on Monday raised its full-year profit forecast, citing stronger demand for the company's surgical devices. Device makers, lately, have been reporting a recovery in sales as staff shortages ease and procedure volumes pick up in hospitals. Last week, peer Edwards Lifesciences Corp raised its sales and profit forecasts for 2023, citing strong demand for the company's artificial heart valves.
Kalamazoo, Michigan, May 01, 2023 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the first quarter of 2023: First Quarter Results Reported net sales increased 11.8% to $4.8 billionOrganic net sales increased 13.6%Reported operating income margin of 15.4%Adjusted operating income margin(1) contracted 70 bps to 21.1%Reported EPS increased 83.3% to $1.54Adjusted EPS(1) increased 8.6% to $2.14 First Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant
Medical device makers are outperforming the general healthcare market so far this year as supply issues ease and the volume of medical procedures is increasing. Three examples are Medtronic (NYSE: MDT), Edwards Lifesciences (NYSE: EW), and Stryker (NYSE: SYK), each of which is up more than 15% this year. The rest of the healthcare industry, on the other hand, has mostly seen its shares decline.
Its valuation should be very attractive or at least reasonable -- otherwise you may buy at such a steep valuation that the stock will be as likely to retreat as to advance. Here are three promising companies whose stocks seem to have gotten ahead of themselves. Hershey (NYSE: HSY) has been a sweet investment for many people, outpacing the S&P 500 over the past decade with an average annual total return of roughly 14% versus 12% for the benchmark index.
Stryker's (SYK) first-quarter results are expected to reflect strong segmental performances. However, rising costs are likely to have continued hurting margins.
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
HAE vs. SYK: Which Stock Is the Better Value Option?
Encompass Health (EHC) is well-poised for growth on the back of growing facility count within its Inpatient Rehabilitation segment and sound liquidity position.
Does Stryker (SYK) have what it takes to be a top stock pick for momentum investors? Let's find out.
Unfortunately, it's almost certain that there will always be patients with chronic medical conditions requiring treatment from healthcare providers. The good news for these patients is that there are many pharmaceutical and medical device companies working to improve existing treatments. In that light, here are two quality healthcare stocks that could be attractive picks for dividend growth investors to buy this month and hold for decades.
Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on the company.